The Economic Burden of Cardiovascular Disease
Despite the extensive literature and research that indicates the preventability of cardiovascular disease, it remains a primary and leading cause of not only mortality & morbidity, but also a tremendous health care cost and economic burden. A Vital Signs report recently released by the Centers for Disease Control and Prevention cited that in 2016 alone, […]
Empagliflozin FDA Approved for Prevention of Cardiovascular Death
In an unprecedented move, the US FDA approved the SGLT-2 inhibitor empagliflozin for the prevention of cardiovascular death in patients with type 2 diabetes and coexisting cardiovascular disease (CVD). Empagliflozin was first approved in 2014 for the treatment of type 2 diabetes and later demonstrated cardiovascular risk reduction in the EMPA-REG trial. Specifically, treatment with […]
